Recent research led by Northwestern University has revealed that metformin, a widely prescribed medication for type 2 diabetes (T2D), primarily exerts its glucose-lowering effects through the gut rather than the liver, as previously believed. The study indicates that metformin inhibits mitochondrial complex I in intestinal cells, effectively transforming the gut into a glucose sink that enhances glucose utilization and lowers blood sugar levels.
This groundbreaking discovery not only clarifies the mechanisms behind metformin’s clinical effects but also opens avenues for new therapeutic strategies targeting mitochondrial metabolism in the gut. Corresponding author Navdeep Chandel, PhD, emphasized the significance of these findings, stating that metformin essentially helps the intestine absorb glucose from the bloodstream, thereby underscoring the gut’s critical role in glucose regulation.
The implications of this research extend beyond metformin itself, as it suggests a similar mechanism may be at play for other compounds like phenformin and berberine, which also engage the same metabolic pathway. This insight could lead to innovative approaches for managing blood sugar levels, particularly in patients for whom traditional therapies are ineffective, thereby enhancing the overall treatment landscape for diabetes.
Start your 7-day trial and see what the database can do →
